About the study

The study will extend through the year 2006 and will examine 600 to 950 women aged 25 to 60 and older. It will assess the clinical safety of the device and its effectiveness under real conditions of use. This study will be conducted at the Central Alberta Medical Imaging Services (CAMIS), at the McGill University Health Centre (MUHC), as well as in additional major centres in North America to be announced in the upcoming months.


ART Advanced Research Technologies Inc. is a leader in optical molecular imaging products for the healthcare and pharmaceutical industries. ART has developed two products based on its innovative technology. The first is eXplore Optix, a molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs. eXplore Optix is distributed by GE Healthcare and is used by industry and academic leaders worldwide to bring new and better treatments to patients faster. The second is SoftScan, a medical imaging device designed to improve the diagnosis and treatment of breast cancer. ART is commercializing its products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. ART's shares are listed on the TSX under the ticker symbol ARA.

The Central Alberta Medical Imaging Services (CAMIS) has been the major imaging provider for central Alberta and the David Thompson Health Region for over 35 years. In 2001, the physicians of Central Alberta Medical Imaging Services, CAMIS, had a vision to provide public health care in a state of the art facility. That vision became reality in February 2004. The facility provides a modern, comfortable, spacious environment for patients waiting for and undergoing diagnostic examinations. CAMIS radiologists are all board certified and the imaging staff are all registered in their various disciplines. The goal of CAMIS is to provide high quality, state of the art, patient-oriented medical imaging.

Back to HCB News

More Voices